TRIPTODUR KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIPTODUR KIT (TRIPTODUR KIT).
Gonadotropin-releasing hormone (GnRH) agonist; continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to decreased testosterone production in males and estrogen production in females.
| Metabolism | Metabolized by peptidases; not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal (approximately 50% as unchanged drug and metabolites); biliary/fecal (approximately 20-30%); the remainder is metabolized. |
| Half-life | Terminal elimination half-life is 28-35 hours in healthy adults, allowing for a 4-week dosing interval. In patients with renal impairment, half-life is prolonged. |
| Protein binding | Approximately 90-95% bound to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Vd is approximately 1.2-1.4 L/kg, indicating distribution into total body water and tissues. |
| Bioavailability | Intramuscular: 100% bioavailability (depot formulation). |
| Onset of Action | Intramuscular injection: Therapeutic effect on testosterone levels observed within 2-4 days; peak suppression of gonadotropins by 2 weeks. |
| Duration of Action | Single IM injection provides effective suppression of testosterone for 4 weeks, supporting monthly dosing. Effect on symptoms persists for 8-12 weeks post-injection due to prolonged release. |
3.75 mg intramuscularly once every 28 days.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use with caution. |
| Liver impairment | No clinical studies in hepatic impairment; use with caution and monitor closely. No specific Child-Pugh based recommendations. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and tolerability closely due to age-related decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIPTODUR KIT (TRIPTODUR KIT).
| Breastfeeding | Not recommended during breastfeeding. Triptorelin is excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant. |
| Teratogenic Risk | TRIPTODUR KIT (triptorelin pamoate) is contraindicated in pregnancy. First trimester exposure carries risk of spontaneous abortion and congenital anomalies due to anti-gonadotropic effects. Second and third trimester: continued use may cause fetal harm from hormonal disruption. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to triptorelin or any component of the formulation","Pregnancy (risk of fetal harm)"]
| Precautions | ["Transient increase in serum testosterone during initial therapy may cause worsening of prostate cancer symptoms (tumor flare)","Hyperglycemia and increased risk of diabetes","Cardiovascular events (myocardial infarction, sudden cardiac death) have been reported","QT interval prolongation","Bone density loss with long-term use"] |
Loading safety data…
| Monitor pregnancy status with serum β-hCG prior to each dose. During pregnancy, if exposure occurs, monitor fetal development via ultrasound and assess for congenital anomalies. |
| Fertility Effects | Reversible suppression of gonadotropin secretion, leading to anovulation and amenorrhea. Long-term use may delay return of fertility; generally reversible upon discontinuation. |